Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Miyamoto H and Messing EM (2004) Early versus late hormonal therapy for prostate cancer. Curr Urol Rep 5: 188–196

    Article  Google Scholar 

  2. Merrick GS et al. (2005) Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61: 32–43

    Article  CAS  Google Scholar 

  3. Sandler HM (2004) Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy. J Urol 172 (Pt 2): S38–S41

    Google Scholar 

  4. D'Amico AV et al. (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292: 821–827

    Article  CAS  Google Scholar 

  5. Messing EM et al. (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781–1788

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Michelmore, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Chawnshang Chang.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Glossary

LOW RISK

Biochemical definition: PSA <10 ng/ml and Gleason score <7 (see GLEASON SCORE)

INTERMEDIATE RISK

Biochemical definition: PSA <10 ng/ml and Gleason score >6, or PSA ≥10 ng/ml and Gleason score <7 (see GLEASON SCORE)

BRACHYTHERAPY

Radiotherapy in which closed sources of radiation (e.g. seeds) are placed (e.g. by implantation) in or close to the area being treated

BIOCHEMICAL RELAPSE

Defined according to the American Society for Therapeutic Radiology and Oncology consensus in patients who underwent brachytherapy or EBRT, and as PSA >0.5 ng/ml in those who underwent RRP

GLEASON SCORE

Sum of grades assigned to the two largest cancerous areas of tissue samples; grades range from 1 (least aggressive) to 5 (most aggressive)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyamoto, H., Messing, E. & Chang, C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?. Nat Rev Clin Oncol 2, 236–237 (2005). https://doi.org/10.1038/ncponc0168

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0168

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing